275 related articles for article (PubMed ID: 7782188)
21. Gd-HP-DO3A in clinical MR imaging of the brain.
Runge VM; Gelblum DY; Pacetti ML; Carolan F; Heard G
Radiology; 1990 Nov; 177(2):393-400. PubMed ID: 2217775
[TBL] [Abstract][Full Text] [Related]
22. Magnetic resonance imaging in a spinal abscess model. Preliminary report.
Runge VM; Williams NM; Lee C; Timoney JF
Invest Radiol; 1998 Apr; 33(4):246-55. PubMed ID: 9556750
[TBL] [Abstract][Full Text] [Related]
23. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
24. Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.
Erstad DJ; Ramsay IA; Jordan VC; Sojoodi M; Fuchs BC; Tanabe KK; Caravan P; Gale EM
Invest Radiol; 2019 Nov; 54(11):697-703. PubMed ID: 31356382
[TBL] [Abstract][Full Text] [Related]
25. Gd HP-DO3A--experimental evaluation in brain and renal MR.
Runge VM; Gelblum DY; Jacobson S
Magn Reson Imaging; 1991; 9(1):79-87. PubMed ID: 2056855
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength.
Fries P; Massmann A; Robert P; Corot C; Laschke MW; Schneider G; Buecker A; Müller A
Invest Radiol; 2019 Sep; 54(9):549-558. PubMed ID: 31033675
[TBL] [Abstract][Full Text] [Related]
27. Hepatic kinetics and magnetic resonance imaging of gadolinium-EOB-DTPA in dogs.
Benness G; Khangure M; Morris I; Warwick A; Burrows P; Vogler H; Weinmann HJ
Invest Radiol; 1996 Apr; 31(4):211-7. PubMed ID: 8721960
[TBL] [Abstract][Full Text] [Related]
28. Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging.
Wolansky LJ; Finden SG; Chang R; Conigliari M; Lee HJ; Shaderowsky PD; Cook SD
Clin Imaging; 1998; 22(6):385-92. PubMed ID: 9876905
[TBL] [Abstract][Full Text] [Related]
29. P03277-A New Approach to Achieve High-Contrast Enhancement: Initial Results of an Experimental Extracellular Gadolinium-Based Magnetic Resonance Contrast Agent.
Fries P; Müller A; Seidel R; Robert P; Denda G; Menger MD; Schneider G; Buecker A
Invest Radiol; 2015 Dec; 50(12):835-42. PubMed ID: 26186281
[TBL] [Abstract][Full Text] [Related]
30. Gd-DISIDA--a potential contrast agent for magnetic resonance imaging of the hepatobiliary system.
Saha GB; Bateson BP; Meaney TF; Ng TC; Go RT; MacIntyre WJ; Feiglin DH; O'Donnell JK
J Nucl Med Allied Sci; 1989; 33(1):1-6. PubMed ID: 2746364
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB
J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
[TBL] [Abstract][Full Text] [Related]
32. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents.
Puttagunta NR; Gibby WA; Smith GT
Invest Radiol; 1996 Dec; 31(12):739-42. PubMed ID: 8970874
[TBL] [Abstract][Full Text] [Related]
33. Delayed magnetic resonance hepatic imaging with gadolinium-DTPA.
Nelson RC; Umpierrez ME; Chezmar JL; Bernardino ME
Invest Radiol; 1988 Jul; 23(7):509-11. PubMed ID: 3170138
[TBL] [Abstract][Full Text] [Related]
34. Three-dimensional multiphase time-resolved low-dose contrast-enhanced magnetic resonance angiography using TWIST on a 32-channel coil at 3 T: a quantitative and qualitative comparison of a conventional gadolinium chelate with a high-relaxivity agent.
Giesel FL; Runge V; Kirchin M; Mehndiratta A; Gerigk L; Corell B; von Gall C; Kauczor HU; Essig M
J Comput Assist Tomogr; 2010; 34(5):678-83. PubMed ID: 20861769
[TBL] [Abstract][Full Text] [Related]
35. Enhanced liver MR: contrast agents and imaging strategy.
Runge VM; Kirsch JE; Wells JW; Awh MH; Bittner DF; Woolfolk CE
Crit Rev Diagn Imaging; 1993; 34(1-2):1-30. PubMed ID: 8216813
[TBL] [Abstract][Full Text] [Related]
36. Gadolinium-phthalein complexone as a contrast agent for hepatobiliary MR imaging.
Kawamura Y; Endo K; Koizumi M; Watanabe Y; Saga T; Konishi J; Horiuchi K; Yokoyama A
J Comput Assist Tomogr; 1989; 13(1):67-70. PubMed ID: 2910950
[TBL] [Abstract][Full Text] [Related]
37. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application.
Caudana R; Morana G; Pirovano GP; Nicoli N; Portuese A; Spinazzi A; Di Rito R; Pistolesi GF
Radiology; 1996 May; 199(2):513-20. PubMed ID: 8668804
[TBL] [Abstract][Full Text] [Related]
38. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.
Petersein J; Spinazzi A; Giovagnoni A; Soyer P; Terrier F; Lencioni R; Bartolozzi C; Grazioli L; Chiesa A; Manfredi R; Marano P; Van Persijn Van Meerten EL; Bloem JL; Petre C; Marchal G; Greco A; McNamara MT; Heuck A; Reiser M; Laniado M; Claussen C; Daldrup HE; Rummeny E; Kirchin MA; Pirovano G; Hamm B
Radiology; 2000 Jun; 215(3):727-36. PubMed ID: 10831691
[TBL] [Abstract][Full Text] [Related]
39. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
